血管紧张素Ⅱ及其1型受体拮抗剂在卵巢癌中的作用机制

doi:10.12280/gjfckx.20210248

摘要/Abstract

摘要：

卵巢癌是女性生殖系统常见的恶性肿瘤之一,由于其发病隐匿,大多数患者出现症状就诊时已属晚期,且易发生转移和复发,死亡率居妇科恶性肿瘤的首位。因此进一步探究卵巢癌发生发展机制、寻找肿瘤潜在治疗靶点至关重要。血管紧张素Ⅱ（angiotensinⅡ,AngⅡ）是肾素-血管紧张素系统（renin-angiotensin system,RAS）中最具生物活性的因子,主要参与机体血压和水盐代谢的调节,目前研究发现其与血管紧张素1型受体（angiotensin type 1 receptor,AT1R）结合激活相关通路与卵巢癌的发生、发展及转移过程密切相关,而AT1R拮抗剂（angiotensin receptor blocker,ARB）可以与AT1R选择性结合阻断AngⅡ-AT1R通路,从而阻断或抑制AngⅡ在卵巢癌中的作用。深入研究血管紧张素Ⅱ及其1型受体拮抗剂在卵巢癌中的作用机制或许能为寻找卵巢癌新的治疗靶点提供依据。

关键词: 卵巢肿瘤, 血管紧张素Ⅱ, 受体,血管紧张素,1型, 血管紧张素Ⅱ1型受体拮抗剂

Abstract:

Ovarian cancer is one of the most common malignant tumors in the female reproductive system. Because of its insidious onset, most patients are already in advanced stage when they have symptoms, and are prone to metastasis and recurrence. The mortality rate of ovarian cancer ranks first among gynecological malignant tumors. Therefore, it is very important to further explore the mechanism of ovarian cancer and find potential therapeutic targets. AngiotensinⅡ(AngⅡ) is the most bioactive factor in renin-angiotensin system (RAS), mainly involved in the regulation of metabolism of the body′s blood pressure and salt water. At present, some studies found that it combined with the angiotensin type 1 receptor (AT1R) to activated related pathways and that is closely related to the process of the occurrence and development of ovarian cancer and metastasis. And AT1R antagonists angiotensin receptor blocker (ARB) can selectively bind to AT1R blocking AngⅡ-AT1R pathways, thereby blocking or inhibit AngⅡrole in ovarian cancer. Further study on the mechanism of AngⅡand its type 1 receptor antagonist in ovarian cancer may provide evidence for new therapeutic targets for ovarian cancer.

Key words: Ovarian neoplasms, Angiotensin Ⅱ, Receptor,angiotensin,type 1, Angiotensin Ⅱ, type 1 receptor blockers

龚礼萍, 孙立涛, 田家玮. 血管紧张素Ⅱ及其1型受体拮抗剂在卵巢癌中的作用机制[J]. 国际妇产科学杂志, 2022, 49(1): 24-28.

GONG Li-ping, SUN Li-tao, TIAN Jia-wei. Mechanism of Angiotensin Ⅱ and Its Type 1 Receptor Blockers in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 24-28.

参考文献 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi: 10.3322/caac.21551. doi: 10.3322/caac.21551
[2]	Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2. doi: 10.1016/S0140-6736(18)32552-2
[3]	Wolgien MDCGM, Correa SAA, Breuel PAF, et al. Renin Angiotensin System Components and Cancer: Reports of Association[J]. J Biosci Med, 2016, 4(5):65-75. doi: 10.4236/jbm.2016.45007. doi: 10.4236/jbm.2016.45007
[4]	Yang J, Zhang X, Yu X, et al. Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation[J]. Int J Mol Med, 2017, 39(3):613-621. doi: 10.3892/ijmm.2017.2856. doi: 10.3892/ijmm.2017.2856 pmid: 28098884
[5]	Xu Z, Li W, Han J, et al. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)[J]. Sci Rep, 2017, 7:44911. doi: 10.1038/srep44911. doi: 10.1038/srep44911
[6]	Zubcevic J, Santisteban MM, Perez PD, et al. A Single Angiotensin II Hypertensive Stimulus Is Associated with Prolonged Neuronal and Immune System Activation in Wistar-Kyoto Rats[J]. Front Physiol, 2017, 8:592. doi: 10.3389/fphys.2017.00592. doi: 10.3389/fphys.2017.00592 pmid: 28912720
[7]	Volonte D, Sedorovitz M, Cespedes VE, et al. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic K-Ras[J]. J Biol Chem, 2021, 296:100242. doi: 10.1074/jbc.RA120.015188. doi: 10.1074/jbc.RA120.015188
[8]	Tu Y, Liu Z, Wang F, et al. AT1R-Specific Ligand Angiotensin II as a Novel SPECT Agent for Hepatocellular Carcinoma Diagnosis[J]. ACS Sens, 2020, 5(12):4072-4080. doi: 10.1021/acssensors.0c02180. doi: 10.1021/acssensors.0c02180
[9]	Acconcia F. The Network of Angiotensin Receptors in Breast Cancer[J]. Cells, 2020, 9(6):1336. doi: 10.3390/cells9061336. doi: 10.3390/cells9061336
[10]	Xu ZW, Yan SX, Wu HX, et al. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression[J]. Dig Liver Dis, 2019, 51(2):263-274. doi: 10.1016/j.dld.2018.06.007. doi: 10.1016/j.dld.2018.06.007
[11]	Pei N, Mao Y, Wan P, et al. Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer[J]. J Exp Clin Cancer Res, 2017, 36(1):77. doi: 10.1186/s13046-017-0542-0. doi: 10.1186/s13046-017-0542-0
[12]	Zhang D, Xi Y, Feng Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies[J]. Eur J Cancer Prev, 2021, 30(2):161-170. doi: 10.1097/CEJ.0000000000000597. doi: 10.1097/CEJ.0000000000000597
[13]	Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review[J]. Cancer Biol Med, 2017, 14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084. doi: 10.20892/j.issn.2095-3941.2016.0084
[14]	Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer[J]. Semin Cancer Biol, 2018, 51:160-169. doi: 10.1016/j.semcancer.2017.08.003. doi: S1044-579X(17)30062-7 pmid: 28782606
[15]	Hao P, Li H, Wu A, et al. Lipocalin2 promotes cell proliferation and migration in ovarian cancer through activation of the ERK/GSK3β/β-catenin signaling pathway[J]. Life Sci, 2020, 262:118492. doi: 10.1016/j.lfs.2020.118492. doi: 10.1016/j.lfs.2020.118492
[16]	Chen Z, Wu M, Liu J. Kelch-like protein 14 promotes proliferation and migration of ovarian cancer cells[J]. Int J Clin Exp Pathol, 2020, 13(12):2950-2961.
[17]	张敏, 杜雨璇, 王洋. 非编码RNA在卵巢癌中的研究现状[J]. 中国临床新医学, 2020, 13(2):207-210. doi: 10.3969/j.issn.1674-3806.2020.02.27. doi: 10.3969/j.issn.1674-3806.2020.02.27
[18]	Lin Z, Liu Y, Sun Y, et al. Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis[J]. J Exp Clin Cancer Res, 2011, 30(1):31. doi: 10.1186/1756-9966-30-31. doi: 10.1186/1756-9966-30-31
[19]	李凡, 毕胜利, 张学林, 等. 血清LRG1、ANG2、OPN联合检测对卵巢癌早期诊断的价值分析[J]. 标记免疫分析与临床, 2020, 27(12):2087-2091. doi: 10.11748/bjmy.issn.1006-1703.2020.12.016. doi: 10.11748/bjmy.issn.1006-1703.2020.12.016
[20]	Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination[J]. Clin Cancer Res, 2005, 11(7):2686-2694. doi: 10.1158/1078-0432.CCR-04-1946. doi: 10.1158/1078-0432.CCR-04-1946
[21]	Ino K, Shibata K, Kajiyama H, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival[J]. Br J Cancer, 2006, 94(4):552-560. doi: 10.1038/sj.bjc.6602961. doi: 10.1038/sj.bjc.6602961
[22]	Hwang SH, Noh SJ, Kwak HJ, et al. Expression of angiotensin II receptor type 1 and 2 in ovarian epithelial tumors[J]. Basic Appl Pathol, 2008, 1(3):131-138. doi: 10.1111/j.1755-9294.2008.00035.x. doi: 10.1111/j.1755-9294.2008.00035.x
[23]	Zhang Q, Yu S, Lam M, et al. Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress[J]. J Exp Clin Cancer Res, 2019, 38(1):116. doi: 10.1186/s13046-019-1127-x. doi: 10.1186/s13046-019-1127-x
[24]	Oh E, Kim JY, Cho Y, et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis[J]. Biochim Biophys Acta, 2016, 1863(6 Pt A):1071-1081. doi: 10.1016/j.bbamcr.2016.03.010. doi: 10.1016/j.bbamcr.2016.03.010
[25]	Herr D, Sauer C, Holzheu I, et al. Role of Renin-Angiotensin-System in Human Breast Cancer Cells: Is There a Difference in Regulation of Angiogenesis between Hormone-Receptor Positive and Negative Breast Cancer Cells?[J]. Geburtshilfe Frauenheilkd, 2019, 79(6):626-634. doi: 10.1055/a-0887-7313. doi: 10.1055/a-0887-7313
[26]	Hashemzehi M, Beheshti F, Hassanian SM, et al. Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis[J]. Pathol Res Pract, 2020, 216(7):153010. doi: 10.1016/j.prp.2020.153010. doi: S0344-0338(20)30589-6 pmid: 32534713
[27]	刘宇平. 血管紧张素Ⅱ对卵巢癌Caov-3细胞的侵袭迁移的影响及机制研究[D]. 贵阳:贵州医科大学, 2019.
[28]	Gunay G, Kirit HA, Kamatar A, et al. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration[J]. Gynecol Oncol, 2020, 159(2):563-572. doi: 10.1016/j.ygyno.2020.09.002. doi: 10.1016/j.ygyno.2020.09.002
[29]	Fritz JL, Collins O, Saxena P, et al. A novel role for NUAK1 in promoting ovarian cancer metastasis through regulation of fibronectin production in spheroids[J]. Cancers (Basel), 2020, 12(5):1250. doi: 10.3390/cancers12051250. doi: 10.3390/cancers12051250
[30]	Li S, Xu HX, Wu CT, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications[J]. Angiogenesis, 2019, 22(1):15-36. doi: 10.1007/s10456-018-9645-2. doi: 10.1007/s10456-018-9645-2
[31]	寻克娟, 钱志红. 血管紧张素Ⅱ受体抑制剂对人卵巢癌细胞抑制作用的研究[J]. 山西医药杂志, 2008, 37(10):881-883. doi: 10.3969/j.issn.0253-9926.2008.10.006. doi: 10.3969/j.issn.0253-9926.2008.10.006
[32]	Park YA, Choi CH, Do IG, et al. Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma[J]. Gynecol Oncol, 2014, 135(1):108-117. doi: 10.1016/j.ygyno.2014.06.031. doi: 10.1016/j.ygyno.2014.06.031
[33]	Zhao Y, Cao J, Melamed A, et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma[J]. Proc Natl Acad Sci U S A, 2019, 116(6):2210-2219. doi: 10.1073/pnas.1818357116. doi: 10.1073/pnas.1818357116
[34]	曹京红, 翟建军. 洛沙坦对人类卵巢癌裸鼠模型腹水的抑制作用[J]. 中华老年医学杂志, 2020, 39(2):209-213. doi: 10.3760/cma.j.issn.0254-9026.2020.02.021. doi: 10.3760/cma.j.issn.0254-9026.2020.02.021
[35]	Cho MA, Jeong SY, Sohn I, et al. Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients[J]. Cancer Res Treat, 2020, 52(2):645-654. doi: 10.4143/crt.2019.509. doi: 10.4143/crt.2019.509